CVR - Coronavirus Vaccines R&D Roadmap

Milestone
1.2.c

Breadth-of-protection panel

In progress
High priority

Prioritize and select coronaviruses that would constitute a panel to be used in vaccine R&D for assessing breadth of protection. Selection criteria should initially focus on coronaviruses that: (1) bind to human host receptors, (2) grow in primary human cells, (3) are phylogenetically diverse, (4) have emerged in multiple species, and (5) have been antigenically characterized.

Progress Highlights

Gordon 2025 describes a NIAID- and CEPI-established panel of select betacoronaviruses to facilitate vaccine R&D:

  • Sarbecoviruses: Wuhan-1, Delta, Omicron BA.4/BA.5, Omicron XBB.1.5, GX-Pangolin, SARS-CoV-1, RsSHC014, BtKY72
  • Merbecoviruses: MERS-CoV, HKU4r-CoV, Neo-CoV
  • Embecoviruses: OC43, HKU1